Is There Evidence of Any Safety Differences Among DPP-4 Inhibitors in the Treatment of People with Type 2 Diabetes Mellitus and Reduced GFR Due to Chronic Kidney Disease?
Crossref DOI link: https://doi.org/10.1007/s13300-015-0104-4
Published Online: 2015-03-18
Published Print: 2015-03
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Evans, Marc
Dejager, Sylvie
Schweizer, Anja
Foley, James E.
Text and Data Mining valid from 2015-03-01
Article History
Received: 18 December 2014
First Online: 18 March 2015